Phensuximide

DB00832

small molecule approved

Deskripsi

Phensuximide is a member of the succinimide class with anticonvulsant properties. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex.

Struktur Molekul 2D

Berat 189.2105
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapid and complete.

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

809 Data
Buprenorphine Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Hydrocodone Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Magnesium sulfate The therapeutic efficacy of Phensuximide can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Phensuximide may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Mirtazapine Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Orphenadrine Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Pramipexole Phensuximide may increase the sedative activities of Pramipexole.
Ropinirole Phensuximide may increase the sedative activities of Ropinirole.
Rotigotine Phensuximide may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Phensuximide.
Sodium oxybate Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Thalidomide Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Mefloquine The therapeutic efficacy of Phensuximide can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Phensuximide can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Phensuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Topotecan Phensuximide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Phensuximide.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Phensuximide.
Ethanol Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Fluvoxamine The risk or severity of adverse effects can be increased when Phensuximide is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Phensuximide is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Phensuximide is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Phensuximide is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Phensuximide is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Phensuximide is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Phensuximide is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Phensuximide is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Phensuximide is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Phensuximide is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Phensuximide is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Phensuximide is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Phensuximide is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Phensuximide is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Phensuximide is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Phensuximide is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Phensuximide is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Phensuximide.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Phensuximide.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Phensuximide.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Phensuximide.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Phensuximide.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Phensuximide.
Cocaine The risk or severity of methemoglobinemia can be increased when Phensuximide is combined with Cocaine.
Quinidine The therapeutic efficacy of Phensuximide can be decreased when used in combination with Quinidine.
Maprotiline The risk or severity of CNS depression can be increased when Phensuximide is combined with Maprotiline.
Doxepin The risk or severity of CNS depression can be increased when Phensuximide is combined with Doxepin.
Desipramine The risk or severity of CNS depression can be increased when Phensuximide is combined with Desipramine.
Pizotifen The risk or severity of CNS depression can be increased when Phensuximide is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Phensuximide is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Phensuximide is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Phensuximide.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Phensuximide.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Phensuximide.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Phensuximide.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Phensuximide.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Phensuximide.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Phensuximide.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Phensuximide.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Phensuximide.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Phensuximide.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Phensuximide.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Phensuximide.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Phensuximide.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Phensuximide.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Phensuximide.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Phensuximide.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Phensuximide.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Phensuximide.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Phensuximide.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Phensuximide.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Phensuximide.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Phensuximide.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Phensuximide.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Phensuximide.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phensuximide.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Phensuximide.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Phensuximide.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Phensuximide.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Phensuximide.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Phensuximide.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Phensuximide.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Phensuximide.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Phensuximide.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Phensuximide.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Phensuximide.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 3772011
    Rankin GO, Cressey-Veneziano K, Wang RT, Brown PI: Urinary tract effects of phensuximide in the Sprague-Dawley and Fischer 344 rat. J Appl Toxicol. 1986 Oct;6(5):349-56.
  • PMID: 14020499
    CHEN G, WESTON JK, BRATTON AC Jr: Anticonvulsant activity and toxicity of phensuximide, methsuximide and ethosuximide. Epilepsia. 1963 Mar;4:66-76.
  • PMID: 38736
    Ferrendelli JA, Kinscherf DA: Inhibitory effects of anticonvulsant drugs on cyclic nucleotide accumulation in brain. Ann Neurol. 1979 Jun;5(6):533-8.

Contoh Produk & Brand

Produk: 0 • International brands: 4
International Brands
  • Lifene — Debat
  • Milontin — Parke-Davis
  • Milonton — BCM Corporation
  • Succitimal — Katwijk

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul